Subscribe To
![](https://ml.globenewswire.com/media/NTgxZGZhOTktNGZlMC00MTc0LWJiMGEtZjFkNjcwNDkyYzg0LTEwMzE1OTg=/tiny/Apellis-Pharmaceuticals-Inc-.png)
Nov 4 2023, 17:37
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated safety profile consistent with previously reported clinical data Approximately 92% of patients enrolled in GALE completed the first year of the study, demonstrating robust long-term compliance Data were presented during an oral […] The post SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Pat... Read More
![](assets/img/profiles/avatar_small.jpg)
forextv